Provided by Tiger Fintech (Singapore) Pte. Ltd.

RenovoRx Inc

0.7910
-0.0390-4.70%
Post-market: 0.83050.0395+4.99%17:36 EDT
Volume:64.65K
Turnover:52.26K
Market Cap:28.91M
PE:-1.98
High:0.8498
Open:0.8414
Low:0.7890
Close:0.8300
Loading ...

Company Profile

Company Name:
RenovoRx Inc
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
8
Office Location:
4546 El Camino Real,Suite B1,Los Altos,California,United States
Zip Code:
94022
Fax:
650 397 4433
Introduction:
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Directors

Name
Position
Ramtin Agah
Chief Medical Officer and Chairman of the Board
Shaun R. Bagai
Chief Executive Officer and Director
David Diamond
Director
Kristen Angela Macfarlane
Director
Laurence J. Marton
Director
Robert Spiegel
Director
Una S. Ryan
Director

Shareholders

Name
Position
Shaun R. Bagai
Chief Executive Officer and Director
Angela Gill Nelms
Chief Operating Officer
James M. Ahlers
Chief Financial Officer
Ramtin Agah
Chief Medical Officer and Chairman of the Board